{
    "symbol": "SMTI",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-16 13:28:13",
    "content": " But our loss when compared to the same period of the previous year was impacted by higher SG&A expenses, which increased $3.9 million as well as higher R&D costs, which increased $1 million, primarily related to our merger with Precision Healing and several other new development projects. Scendia's unaudited full-year 2021 revenue was $8.3 million and unaudited trailing 12-months revenue was $11 million as of May 31, 2022. For the three months ended June 30, 2022, we generated net revenues of $9.7 million compared to net revenues of $6.3 million for the three months ended June 30, 2021, representing a 54% increase from the prior-year period. For the six months ended June 30, 2022, net revenues totaled $17.5 million compared to net revenues of $11.3 million for the same period last year, representing a 55% increase from the prior-year period. SG&A expenses for the three months ended June 30, 2022, were $10.4 million as compared to $6.6 million for the three months ended June 30, 2021. SG&A expenses for the six months ended June 30, 2022, were $19.8 million compared to SG&A expenses of $12 million for the same period last year. We had a net loss of $3.3 million for the three months ended June 30, 2022, compared to a net loss of $1.2 million for the three months ended June 30, 2021. For the six-months period ended June 30, 2022, we had a net loss of $6.4 million compared to a net loss of $2.4 million for the same period last year."
}